儿童重症肺炎支原体肺炎的诊治进展

Progress in the diagnosis and treatment of severe pediatric Mycoplasma pneumoniae pneumonia

近年来,东亚国家特别是我国报道的学龄期儿童肺炎支原体肺炎(MPP)重症及耐药病例数量在增多。儿童MPP是异质性疾病,部分患儿感染后为自限性过程,部分患儿感染后病情重且迁延,容易遗留下气道闭塞的后遗症,导致这部分患儿肺功能减退,生活质量下降。虽然目前我国尚无儿童MPP的全国流行病学数据,但基于我国学龄期儿童人口基数大,以及MPP遗留下气道闭塞的长期影响,MPP应被视为我国学龄期儿童主要的呼吸系统疾病并加以重视。现主要就肺炎支原体耐药与重症MPP的关系,以及MPP的分型和治疗进行简要概述。

In recent years,the number of severe and drug-resistant Mycoplasma pneumoniae pneumonia(MPP)in school-aged children in East Asian countries is on the rise,especially in China.Pediatric MPP is a heterogeneous disease.Some MPP children have a self-limited progression after infection,while some suffer an aggravated and prolonged course of disease.The sequelae of airway occlusion leads to the declines of lung function and quality of life.Although a series of nationally epidemiological data on pediatric MPP in China are scant,pediatric MPP should be regarded as the highly concerned main respiratory disease of school-aged children due to the large population of children in China and the long-term effects of MPP-induced airway occlusion.This article briefly reviews the correlation between Mycoplasma pneumoniae resistance and severe MPP,as well as the classification and treatment of MPP.